实用医学杂志 ›› 2023, Vol. 39 ›› Issue (8): 1029-1034.doi: 10.3969/j.issn.1006⁃5725.2023.08.019

• 药物与临床 • 上一篇    下一篇

右美托咪定对术后导尿管相关膀胱刺激征的影响 

程二红1 石润涵1 刘金东2 范从海1    

  1. 1 徐州医科大学麻醉学院(江苏徐州 221000);2 徐州医科大学附属医院麻醉科(江苏徐州 221000)
  • 出版日期:2023-04-25 发布日期:2023-04-25
  • 通讯作者: 范从海 E⁃mail:852401215@qq.com
  • 基金资助:
    江苏省医院协会医院管理创新研究基金(编号:JSYGY⁃3⁃2019⁃515);徐州市科技项目研究基金(编号:KC17199) 

Effect of dexmedetomidine on postoperative urinary catheter⁃related bladder discomfort

CHENG Erhong*, SHI Runhan,LIU Jindong,FAN Conghai.   

  1. School of Anesthesiology,Xuzhou Medical University,Xuzhou 221000, China

  • Online:2023-04-25 Published:2023-04-25
  • Contact: FAN Conghai E⁃mail:852401215@qq.com

摘要:

目的 观察不同剂量右美托咪定对术后导尿管相关膀胱刺激征(CRBD)的影响,探讨右美托咪定与术后膀胱刺激征症状的量效关系,为临床选择适宜剂量提供依据。方法 选取择期全麻手 术计划导尿的男性患者 303 例,分为生理盐水对照组(A 组)、右美托咪定 0.2 μg/(kg·h)组(B 组)、0.4 μg/(kg· h)组(C 组)和 0.6 μg/(kg·h)组(D 组)。B、C、D 组均在诱导前输注负荷剂量右美托咪定 1 μg/ kg(10 min 内泵注完成),后分别以 0.2 μg/(kg·h)、0.4 μg/(kg·h)、0.6 μg/(kg·h)的剂量泵注,A 组给予 等量生理盐水,手术结束前 30 min 停止。于恢复室(T0)、术后 1 h(T1)、6 h(T2)、24 h(T3)评估患者 CRBD 的发生率及严重程度。记录术中药物使用情况及术后不良反应。结果 CRBD 比较,在 T0、T2时 A 组与 B、C、D 三组相比差异有统计学意义(P < 0.05);在 T1时 A 组与 B、C、D 三组以及 B 组与 D 组之间差 异有统计学意义(P < 0.05);在 T3 时 C 组、D 组 CRBD 发生率低于 A 组(P < 0.05)。在 T0、T1、T2时 D 组中 重度 CRBD 的发生率低于 A 组,差异有统计学意义(P < 0.05)。在 T0、T1、T2时 4 组之间的 NRS 评分差异 有统计学意义(P < 0.05)。在 T3时,对照组 NRS 评分高于所有右美托咪定组,但右美托咪定组之间差异无 统计学意义。随着右美托咪定剂量增加,术中瑞芬太尼和丙泊酚的使用量降低(P < 0.05)。4 组不良反 应的发生率差异无统计学意义(P > 0.05)。结论 术中给予右美托咪定可降低术后 CRBD 的发生率。 0.6 μg/(kg·h)的剂量在降低 CRBD 发生率的同时可以降低严重程度,此剂量可提高患者的舒适度且无 相关不良反应。

关键词: 导尿管相关膀胱刺激征, 右美托咪定, 男性, 非泌尿外科

Abstract:

Objective To observe the effect of different doses of dexmedetomidine on catheter ⁃ related bladder discomfort(CRBD),to explore the appropriate dose of dexmedetomidine during operation. Methods A total of 303 male patients undergoing elective surgery under general anesthesia and planned to insert catheter were selected and randomly divided into four groups:normal saline control group(group A),dexmedetomidine 0.2 μg/(kg·h) group(group B),0.4 μg/(kg·h)group(group C),and 0.6 μg/(kg·h)group(group D). Groups B,C and D were infused with loading dose of dexmedetomidine 1 μg/kg before induction(completed by intravenous pumping within 10 min),and then were continuously pumped with 0.2 μg/(kg·h),0.4 μg/(kg· h),0.6 μg/(kg·h)respectively. Group A was given the same amount of normal saline. The infusion was stopped until 30 minutes before the end of the operation. The incidence and severity of CRBD were evaluated at the postanesthesia care unit(PACU)(T0), 1 h(T1),6 h(T2),and 24 h(T3)after operation. Intraoperative drug use and postoperative adverse events were recorded. Results The incidence of CRBD,at T0,T2,there were differences between group A and B,group A and C,and group A and D(P < 0.05). At T1,there were differences between group A and group B,group A and group C,group A and group D,and between group B and group D(P < 0.05). At T3,there were differences between group A and group C,and group A and group D(P < 0.05). At T0,T1 and T2,the incidences of moderate to severe CRBD in group D were statistically different from group A(P < 0.05). The NRS scores of the four groups at T0,T1 and T2 were statistically significant(P < 0.05). At T3,the control group was higher than that of the dexme⁃ detomidine group,but there was no significant difference between the dexmedetomidine groups. The use of remifen⁃ tanil and propofol decreased with the increase of dexmedetomidine dose,which was statistically significant among the four groups. There was no significant difference in the incidence of adverse reactions among the four groups (P > 0.05). Conclusions Intraoperative administration of dexmedetomidine can reduce the incidence of postoper⁃ ative CRBD,The dose of 0.6 μg/(kg · h)can reduce the incidence and severity of CRBD,and this dose can improve the comfort of patients without related adverse reactions.

Key words:

catheter?related bladder discomfort, dexmedetomidine, male, non urological surgery